A clinical study underway at Rex Cancer Center of Wakefield will evaluate the use of telemonitoring in managing administration of Gleevec, a drug developed and manufactured by Novartis to treat chronic myeloid leukemia. The study will assess the use of a cellphone-based, personalized drug management system called eMedonline to help manage patients' compliance with Gleevec, and help identify and manage side effects.
Many new cancer treatments are delivered orally, offering convenient administration and the potential for improved quality of life. However, patient compliance is of concern. A review of cancer patient noncompliance published in the Journal of the National Cancer Institute found that up to 80% failed to follow their prescriptions.
"Healthcare reform will fail without technologies to more efficiently manage and communicate with patients," said Robert Wehbie, MD, principal investigator on the study and oncologist at Rex. "Technology like eMedonline is uniquely positioned to provide this capability."
The eMedonline platform is designed to facilitate compliance data collection and help manage dosing. It was developed by Leap of Faith Technologies under a grant from the National Institute on Aging and a contract with the National Cancer Institute. It has consistently demonstrated adherence rates of 98%, along with clinically significant improvements in self efficacy, in randomized control studies among chronic disease and cancer patients.